Results 121 to 130 of about 75,057 (290)

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib

Current Research in Pharmacology and Drug Discovery
Non-small-cell lung cancer (NSCLC) represents a predominant histological subtype of lung cancer, characterized by high incidence and mortality rates.
Jing Zhang, Zequn Wang, Xihua Wei, Mengyuan Han, Ribai Yan, Lijie Ma, Yan Pan   +6 more
doaj   +1 more source

MiR-9 Promotes Angiogenesis via Targeting on Sphingosine-1- Phosphate Receptor 1

Frontiers in Cell and Developmental Biology, 2020
We previously demonstrated that vascular endothelial cells released VEGF-enriched exosomes to promote the tumor vasculogenesis and progression after anti-angiogenic therapies (AATs).
Xinghong Yao, Xinghong Yao, Linshen Xie, Ye Zeng   +3 more
doaj   +1 more source

Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease [PDF]

, 2018
Huntington's disease (HD) is themost common neurodegenerative disorder for which no effective cure is yet available. Although several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only ...
Amico, Enrico, Buttari, Fabio, Capocci, Luca, Castaldo, Salvatore, Di Pardo, Alba, Giovannelli, Alfredo, Madonna, Michele, Maglione, Vittorio, Marracino, Federico, Pepe, Giuseppe, van Bergeijk, Jeroen, van der Kam, Elizabeth   +11 more
core   +1 more source

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Drugs, 2017
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators.
G. Comi, H. Hartung, R. Bakshi, Ian M. Williams, H. Wiendl   +4 more
semanticscholar   +1 more source

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers

Movement Disorders, EarlyView.
Abstract Background GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease.
Julian Agin‐Liebes, Alexander Haimovich, Rachel Griep, Nathan Galen Hatcher, Lihang Yao, Cheryl Waters, Shalini Padmanabhan, Roy N. Alcalay   +7 more
wiley   +1 more source

The glucocorticoid-Angptl4-ceramide axis induces insulin resistance through PP2A and PKCζ. [PDF]

, 2017
Chronic glucocorticoid exposure is associated with the development of insulin resistance. We showed that glucocorticoid-induced insulin resistance was attenuated upon ablation of Angptl4, a glucocorticoid target gene encoding the secreted protein ...
Benjamin, Daniel I, Chen, Tzu-Chieh, Costello, Damian E, Kuo, Taiyi, Lee, Rebecca A, Li, Mei-Lan, Mar, Darryl J, Nomura, Daniel K, Wang, Jen-Chywan   +8 more
core   +1 more source

Enhancing Selective Brain Cancer Therapy: Integrating Nanomedicine and Molecular Dynamics to Target the Cancerous Lipid Composition

Nano Select, EarlyView.
Improving selectivity within therapeutic design is critical to ensure targeted delivery to brain tumors. Targeting the cellular membrane composition distinctive of the blood–brain barrier and brain cancer cells is explored in this review. Nanomedicine can be utilized for precise tumor recognition, and detailed mechanistic interactions of therapeutics ...
Mahnoor Kadri, Dominique de Jong‐Hoogland, Martin B. Ulmschneider   +2 more
wiley   +1 more source

A guide to selecting high-performing antibodies for S1PR1 (UniProt ID: P21453) for use in western blot, immunoprecipitation, and immunofluorescence [version 3; peer review: 2 approved, 1 approved with reservations]

F1000Research
Sphingosine 1-phosphate receptor 1 (S1PR1) is a G-coupled protein receptor that induces crucial biological processes when bound by sphingosine 1-phosphate. Here, we have characterized nine S1PR1 commercial antibodies for western blot, immunoprecipitation,
Carl Laflamme, Sara González Bolívar, Kathleen Southern, Riham Ayoubi, Maryam Fotouhi, Charles Alende   +5 more
doaj   +1 more source

Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents

Journal of Neuroinflammation, 2020
Opioid therapies for chronic pain are undermined by many adverse side effects that reduce their efficacy and lead to dependence, abuse, reduced quality of life, and even death.
Timothy M. Doyle, Mark R. Hutchinson, Kathryn Braden, Kali Janes, Vicky Staikopoulos, Zhoumou Chen, William L. Neumann, Sarah Spiegel, Daniela Salvemini   +8 more
doaj   +1 more source

Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation

Mediators of Inflammation, 2017
The sphingolipid sphingosine-1-phosphate (S1P) emerges as an important regulator of immunity, mainly by signaling through a family of five specific G protein-coupled receptors (S1PR1–5).
Catherine Olesch, Christian Ringel, B. Brüne, A. Weigert   +3 more
semanticscholar   +1 more source